BRITISH COLUMBIA, Canada--(BUSINESS WIRE)--InNexus Biotechnology Inc. (OTCBB:IXSBF) (TSX VENTURE:IXS), a drug development company commercializing the next generation of monoclonal antibodies based on its Dynamic Cross Linking (DXL™) technology, today announced that Maurizio Zanetti, M.D., Professor with the University of California, San Diego, Department of Medicine, Tumor Growth, Invasion & Metastatis Program, has joined the InNexus Scientific Advisory Board. Dr. Zanetti joins Dr. J. Donald Capra, President Emeritus of the Oklahoma Medical Research Foundation and InNexus SAB Chairman, Dr. John D. Minna, Dr. Carlos L. Arteaga, Dr. Ellen Vitetta, Dr. Martin Weigert and Dr. Judith James.